Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease
AssigneeCrinetics Pharmaceuticals, Inc.
InventorsChristine FERRARA-COOK, Alan S. KRASNER
Life of this patent
Estimating the term…
Abstract
Provided herein are methods and compositions for the treatment of diseases of ACTH excess, such as Cushing's disease, ectopic ACTH syndrome, and congenital adrenal hyperplasia.
Claims25
-16. (canceled)
A method of treating congenital adrenal hyperplasia (CAH) in a human, the method comprising administering to the human in need thereof, a compound having the structure of Compound 1, or a pharmaceutically acceptable salt, or solvate thereof:
The method of claim 39, wherein the classical CAH comprises salt-losing CAH or simple-virilizing CAH.
(canceled)
(canceled)
(canceled)
(canceled)
-60. (canceled)
Dependencies are inferred from the claim text.